JP2024528967A5 - - Google Patents
Info
- Publication number
- JP2024528967A5 JP2024528967A5 JP2024506528A JP2024506528A JP2024528967A5 JP 2024528967 A5 JP2024528967 A5 JP 2024528967A5 JP 2024506528 A JP2024506528 A JP 2024506528A JP 2024506528 A JP2024506528 A JP 2024506528A JP 2024528967 A5 JP2024528967 A5 JP 2024528967A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228509P | 2021-08-02 | 2021-08-02 | |
| US63/228,509 | 2021-08-02 | ||
| US202163278899P | 2021-11-12 | 2021-11-12 | |
| US63/278,899 | 2021-11-12 | ||
| PCT/US2022/039192 WO2023014727A1 (en) | 2021-08-02 | 2022-08-02 | Systems and methods for the treatment of hemoglobinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528967A JP2024528967A (ja) | 2024-08-01 |
| JP2024528967A5 true JP2024528967A5 (https=) | 2025-08-08 |
| JPWO2023014727A5 JPWO2023014727A5 (https=) | 2025-08-08 |
Family
ID=83050049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506528A Pending JP2024528967A (ja) | 2021-08-02 | 2022-08-02 | ヘモグロビン異常症の治療のためのシステム及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335476A1 (https=) |
| EP (1) | EP4381068A1 (https=) |
| JP (1) | JP2024528967A (https=) |
| KR (1) | KR20240043772A (https=) |
| AU (1) | AU2022325054A1 (https=) |
| CA (1) | CA3226886A1 (https=) |
| WO (1) | WO2023014727A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4630554A1 (en) * | 2022-12-05 | 2025-10-15 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2026027887A2 (en) * | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016261358B2 (en) | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
| CN110382692A (zh) | 2016-04-19 | 2019-10-25 | 博德研究所 | 新型crispr酶以及系统 |
| WO2019178426A1 (en) * | 2018-03-14 | 2019-09-19 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP4069829A1 (en) | 2019-12-08 | 2022-10-12 | Editas Medicine, Inc. | Modified cells and methods for the treatment of hemoglobinopathies |
-
2022
- 2022-08-02 JP JP2024506528A patent/JP2024528967A/ja active Pending
- 2022-08-02 KR KR1020247006536A patent/KR20240043772A/ko active Pending
- 2022-08-02 CA CA3226886A patent/CA3226886A1/en active Pending
- 2022-08-02 EP EP22758343.2A patent/EP4381068A1/en active Pending
- 2022-08-02 WO PCT/US2022/039192 patent/WO2023014727A1/en not_active Ceased
- 2022-08-02 US US18/294,995 patent/US20240335476A1/en active Pending
- 2022-08-02 AU AU2022325054A patent/AU2022325054A1/en active Pending